# Abcam

> Abcam supplies antibodies, immunoassays, proteins, gene-edited cell lines and related research tools to academic, pharmaceutical, biotechnology and diagnostics laboratories. Founded in Cambridge after a researcher struggled to find a dependable BRCA2 antibody, the company built its reputation on rich product data and fast online ordering, then moved deeper into proprietary recombinant antibodies, knockout validation, biophysical quality control and custom partnerships. Danaher acquired Abcam for approximately $5.7 billion in 2023; today the brand says it supports about 750,000 researchers in more than 130 countries.

- **Founded:** 1998
- **Headquarters:** Cambridge, United Kingdom
- **Founders:** Jonathan Milner (Principal founder and former CEO), David Cleevely (Co-founder and early investor), Tony Kouzarides (Co-founder)
- **Team size:** Approximately 1,800 employees at the end of 2022; LinkedIn listed about 1,878 employee profiles in August 2026.
- **Products:** Antibody and reagent catalog, SimpleStep ELISA, Recombinant antibodies and RabMAb products, Knockout cell lines and knockout validation, Custom Products and Licensing
- **Notable:** Built a customer base of approximately 750,000 researchers across more than 130 countries., Created a catalog that currently includes 37,000 recombinant antibodies and 4,900 knockout-validated recombinant antibodies., Withdrew more than 60,000 products from 2010 onward as validation and quality standards increased.

## Products & services

- **Antibody and reagent catalog** — A searchable global catalog spanning primary and secondary antibodies, proteins, peptides, lysates, biochemicals, conjugates and research kits, supported by application data and technical guidance.
- **SimpleStep ELISA** — Ready-to-use, single-wash immunoassay kits that reduced a conventional multi-hour ELISA workflow to about 90 minutes.
- **Recombinant antibodies and RabMAb products** — Sequence-defined monoclonal antibodies designed for specificity, sensitivity, scalability and batch-to-batch consistency; the current site lists 37,000 recombinant antibodies.
- **Knockout cell lines and knockout validation** — Gene-edited negative controls and antibodies tested against knockout material to expose off-target binding; the current catalog highlights 4,900 knockout-validated recombinant antibodies.
- **Custom Products and Licensing** — Antibody discovery, development, validation, bulk supply and licensing for research platforms, diagnostics and clinical applications, including the ‘Abcam Inside’ partner model.
- **SimpleStep Ignite ELISA** — A chemiluminescent assay platform promising results in 55 minutes, 50 times greater sensitivity and up to 35 times broader measuring range than conventional colorimetric ELISAs.
- **MollAI product guidance** — An AI-assisted tool on Abcam’s website that provides product recommendations to help researchers narrow a large catalog.

## Achievements

- Built a customer base of approximately 750,000 researchers across more than 130 countries.
- Created a catalog that currently includes 37,000 recombinant antibodies and 4,900 knockout-validated recombinant antibodies.
- Withdrew more than 60,000 products from 2010 onward as validation and quality standards increased.
- Reported that proprietary in-house products generated 67% of 2022 revenue, up from 61% in 2021.
- Commercialized more than 2,000 Abcam antibody clones through partner platforms or diagnostic tools by the end of 2022.
- Won CiteAb recognition for a 12th consecutive year in 2026, including IHC Supplier of the Year in Neuroscience and an individual award for Will Howat.
- Completed a roughly $5.7 billion acquisition by Danaher in December 2023.
- Expanded from antibodies into immunoassays, conjugation, cell engineering, proteins, biochemical assays and licensing.

## Latest updates

- **2026-08** — Abcam highlighted selected antibodies in Mabtech’s EYRAplex customizable multiplex panels and promoted its new immunometabolism flow portfolio.
- **2026-04** — Launched SimpleStep Ignite, a 55-minute chemiluminescent ELISA platform marketed with 50-fold greater sensitivity and up to 35-fold broader measuring range.
- **2026-03** — Received three CiteAb recognitions, marking the 12th consecutive year in which Abcam was honored by the awards program.
- **2025-05** — Its Cambridge My Green Lab program achieved two platinum certifications and one silver certification following operational changes.
- **2025-04** — Won CiteAb’s Antibody Supplier Succeeding in Genetics Research award and was highly commended in another category.
- **2024-07** — Received a Silver Award in Stonewall’s 2024 Workplace Equality Index for LGBTQ+ inclusion.
- **2023-12** — Became an indirect wholly owned subsidiary of Danaher; its Nasdaq trading was suspended.

## Links

- Website: https://www.abcam.com/
- LinkedIn: https://www.linkedin.com/company/abcam
- Twitter/X: https://x.com/abcam
- YouTube: https://www.youtube.com/@abcamofficial
- Instagram: https://www.instagram.com/abcamofficial/
- Facebook: https://www.facebook.com/abcam/

---

Profile page: https://yespress.io/abcam
Published by YesPress — https://yespress.io
Last updated: 2026-08-13